Recon: Novartis bags EU authorization for CML drug Scemblix; AZ'...
08/29/22
Recon: Novartis bags EU authorization for CML drug Scemblix; AZ's Farxiga cuts death risk for heart failure patients Regulatory Focus
[more]- Feeds Categories: